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THE EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN 
ELDERLY PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION 
 
DAYEUN LEE 
ABSTRACT 
Clostridium difficile infection (CDI) is the most common hospital-associated infection 
worldwide and is a significant threat in public health, causing morbidity, mortality, and 
healthcare costs. It is caused by C. difficile, ubiquitous, gram-positive, spore-forming 
bacteria that colonize in patients with a disruption in normal intestinal microflora. In the 
past, antibiotics were recommended as standard therapies. However, as treatments that 
involve the use of antibiotics have been associated with high rates of recurrence, recent 
advancements have been made to treat patients with CDI. One of these alternative 
therapies is fecal microbiota transplantation (FMT) that aims to restore colonic flora 
using samples collected from healthy donors. As the elderly population is at a higher risk 
for CDI, this study aims to review published literature to determine the efficacy and 
limitations of current treatment options available for elderly patients with CDI.  
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INTRODUCTION 
An overview of human microbiota 
The number of bacteria in the gastrointestinal tract of the human body is 
estimated to be 100 trillion, which is greater than ten times the number of human cells in 
the body (Ley, Peterson, & Gordon, 2006). Although more than 50 bacterial phyla have 
been identified, only two phyla, Bacteroidetes and Firmicutes, are known to predominate 
the human intestinal tract (Eckburg et al., 2005). The commensal bacteria have been 
found to play many roles, including metabolizing indigestible polysaccharides, protecting 
against pathogens (Ubeda, Djukovic, & Isaac, 2017), providing resistance to epithelial 
cell injury (Rakoff-Nahoum, Paglino, Eslami-Varzaneh, Edberg, & Medzhitov, 2004), 
regulating fat storage (Backhed et al., 2004), and stimulating intestinal angiogenesis 
(Stappenbeck, Hooper, & Gordon, 2002).  
 
The first colonization of the intestine was originally thought to occur at the time 
of birth (Slattery, MacFabe, & Frye, 2016). However, recent studies have found that the 
development of gut microbiome occurs in utero. Following birth, infants continue to 
develop under the influence of many factors, including mode of delivery, diet, and 
environment, which over time determines the infants’ susceptibility or resistance to 
certain diseases (Biasucci et al., 2010).  
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Human Microbiome Project 
To identify these microorganisms and determine their roles in maintaining health, 
the Human Microbiome Project (HMP) was established in 2008. The goal was to 
generate a database and a tool to analyze the human microbiome (Group et al., 2009). It 
was the first metagenomic microbiome survey to be conducted on a population scale. 
During the first phase of HMP, 4,788 specimens were collected across 18 clinically 
relevant body sites from 242 healthy participants (129 males and 113 females) aged 18-
40. The body habitats were roughly divided into five groups: gastrointestinal, urogenital, 
nasal, oral, and skin (Human Microbiome Project, 2012a). Microbial diversity refers to 
the abundance and distribution of different types of microbes within a body site. Results 
from the study indicated that each sampling site within an individual had unique 
microbial composition as assessed by the variation in the genomic data. The diversity 
within an individual was the highest in the mouth and the lowest in the vagina (Figures 1a 
and 1b). Among individuals, the overall composition of the microbiome was found to 
vary; however, there was not much difference in the microbial diversity when comparing 
same body sites between individuals (Figure 1c). The variation between subjects in terms 
of microbial composition and metabolic function was determined to be higher than the 
variation within an individual (Figure 1d) (Human Microbiome Project, 2012b).  
 3 
 
Figure 1. Diversity of human microbiome across different body habitats within and 
among individuals. a. Within-subject alpha diversity separated by body habitats. Cyan = 
genus-level phylotypes, blue = 16S rRNA OTUs, orange = shotgun metagenomics 
matching reference genomes, dark orange = functional modules, and yellow = enzyme 
families. The highest diversity is seen in the mouth, and the lowest diversity is seen in the 
vagina. b. Between-subject diversity separated by body habitats. See a for color legends. 
c. Between-subject variations showing primary clustering is grouped by body habitats. d. 
Repeats of samples from one subject (blue) are more similar than microbial diversity 
from different individuals (red). From The Human Microbiome Project Consortium, 
2012. 
 
In addition to the diversity observed in the human microbiome, it was noted that 
in the healthy individuals, the abundance of any organism or biological agent included in 
the pathogen priority list from National Institute of Allergy and Infectious Diseases 
(NIAID) was less than 0.1% (Human Microbiome Project, 2012b). This possibly reflects 
that even though there exists a between-subject diversity, the microbiota of healthy 
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individuals can be distinct from diseased individuals. These results were used as a 
groundwork to further investigate how the changes in the composition of microbiomes 
lead to diseases and in turn whether the composition could be manipulated to treat 
diseases. 
 
Dysbiosis of microbiota and CDI 
As part of the growing interest in human microbiota, many diseases have been 
linked to a perturbation in intestinal microbial composition (Table 1).  
Table 1. Disorders associated with perturbed intestinal microbiome. 
Gastrointestinal 
Cholelithiasis 
Colorectal cancer 
Hepatic encephalopathy 
Idiopathic constipation 
Irritable bowel syndrome 
Irritable bowel disease 
Familial Mediterranean fever 
Gastric carcinoma and lymphoma 
Recurrent clostridium difficile infection 
Non-gastrointestinal 
Arthritis 
Asthma 
Atopy 
Autism 
Autoimmune disorders 
Chronic fatigue syndrome 
Diabetes mellitus and insulin resistance 
Eczema 
Fatty liver 
Fibromyalgia 
Hay fever 
Hypercholesterolemia 
Idiopathic thrombocytopenic purpura 
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Ischemic heart disease 
Metabolic syndrome 
Mood disorders 
Multiple sclerosis 
Myoclonus dystonia 
Obesity 
Oxalic acid kidney stones 
Parkinson’s disease 
From Brandt 2013. 
 
Clostridium difficile infection (CDI) is a prominent example, where a dysbiosis of 
normal gut flora allows proliferation of Clostridium difficile (C. difficile) spores that 
leads to illnesses ranging from a mild diarrhea to death. It is estimated that there are 
500,000 CDI cases and 29,000 deaths associated with CDI in the United States in a year 
(Shrestha, Bime, & Taleban, 2018). C. difficile is a gram-positive, spore-forming, 
anaerobic bacterium that colonizes the colon of some individuals and become 
metabolically active and cause enterocyte apoptosis, inflammation, diarrhea, and 
pseudomembranous colitis (Abt, McKenney, & Pamer, 2016). 
 
The pathogenesis greatly depends on the ability of the bacteria to undergo spore 
germination and toxin production. The anoxic environment of the lumen of the human 
colon provides a favorable condition for anaerobic C. difficile spores to vegetate and 
produce two toxins, A and B. These spores are heat- and oxygen-resistant and cannot be 
eliminated by ethanol-based sanitizers available in hospitals and other care facilities. The 
germination of C. difficile occurs primarily in the lower gastrointestinal tract, favored by 
negligible amount of oxygen and abundance of bile acids. Interestingly, whereas primary 
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bile acids create conditions that are favorable for the vegetative growth of C. difficile, 
secondary bile acids suppresses vegetative growth (Figure 2). This could explain how 
antibiotic use could decrease the number of commensal bacteria that produce secondary 
bile acids, which in turn leads to increased risk of CDI (Abt et al., 2016). Once 
germination is initiated, the C. difficile spore grows into a vegetative cell that is 
metabolically active and secretes toxins A and B when nutrients are limited. These toxins 
are proteins that when released, glycosylate and inactivate RHO and RAC GTPases in the 
cytosol of targeted host cells. As a result, these toxins affect the cytoskeleton and tight 
junctions between colonic epithelial cells, ultimately disrupting the epithelial integrity of 
the host (Lyras et al., 2009). 
 
CDI is diagnosed based on clinical symptoms, such as diarrhea and abdominal 
pain, and stool tests. In some cases, where CDI is highly likely despite normal results, 
endoscopy or radiology is used for diagnosis. Clinically, CDI is characterized by 
diarrhea, defined as having at least 3 events in a day or 8 events in 2 days, abdominal 
pain, leukocytosis, low-grade fever, decreased renal function, and in some cases 
pseudomembranous colitis. Symptoms of severe or complicated CDI can include 
hypotension, shock, sepsis, perforation and even result in death secondary to CDI 
(Asempa & Nicolau, 2017). Risk factors of CDI include the use of concomitant 
antibiotics, narcotics, or anti-motility agents, and comorbid conditions like acute kidney 
injury or chronic kidney disease. Increasing age is another important risk factor for CDI. 
In particular, the elderly population is highly vulnerable to CDI, supported by an 
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epidemiological study in which an incidence of people aged 65 years and older is 6 times 
higher than that of people aged 45-65 years.  
 
 
Figure 2. Germination of C. difficile spores. When nutrients are limited, “the 
transcription factor stage 0 sporulation protein A (Spo0A)” is phosphorylated, which in 
turn activates a cascade of signaling events and morphological changes that result in the 
creation of a forespore within the bacterium. After lysis, spore is released into the 
environment. Bile acids, such as taurocholate, signal the spore to undergo germination 
and results in a creation of a new vegetative cell. From Abt et al., 2016. 
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PUBLISHED STUDIES 
 
Use of antibiotics for the treatment of CDI 
According to the guidelines updated by the Infectious Diseases Society of 
America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), there are 
several treatment strategies available for CDI. First, it is recommended that patients stop 
using any inciting antibiotic as soon as possible. Studies have shown that continued use 
of concomitant antibiotics increased the risk of recurrent CDI and decreased the cure rate 
of CDI (Mullane et al., 2011).  
 
For the initial, non-severe episode of CDI, defined as the presence of leukocytosis 
with a white blood cell (WBC) count of less than 15,000 cells/mL and a serum creatinine 
level of less than 1.5 mg/dL, the recommended treatment is taking either vancomycin 
(125 mg taken orally 4 times daily) or fidaxomicin (200 mg taken twice a day) for 10 
days. These recommendations also apply to the initial, severe episode of CDI, defined as 
the presence of leukocytosis with a WBC count of greater than 15,000 cells/mL or a 
serum creatinine level of greater than 1.5 mg/dL (McDonald et al., 2018). If first 
recurrence of CDI occurs, the recommended treatment involves the administration of oral 
vancomycin or fidaxomicin according to a tapered and pulsed plan, rather than starting 
another 10-day therapy of vancomycin or fidaxomicin. For subsequent recurrence of 
CDI, antibiotic treatment options include oral vancomycin using tapered and pulsed 
regimen, a standard oral vancomycin treatment followed by rifaximin or fidaxomicin. Of 
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these recommendations, fidaxomicin seems to be better at preventing recurrences 
(Mullane et al., 2011). Table 2 summarizes the clinical guidelines for treating CDI along 
with their strengths and the quality of evidence. 
Table 2. Clinical guidelines for the treatment of CDI 
Description 
of Event 
Clinical Data Recommended Treatment 
Regimen 
Strength of 
Recommendation/ 
Quality of 
Evidence 
First 
episode, low 
severity 
Leukocytosis; 
white blood cell 
count < 15,000 
cells/mL and 
serum creatinine 
level < 1.5 
mg/dL 
 Give 125 mg 
vancomycin 4 times per 
day, or  
 200 mg fidaxomicin 
twice a day 
Strong/High 
 
Strong/High 
First 
episode, high 
severity 
Leukocytosis; 
white blood cell 
count > 15,000 
cells/mL or 
serum creatinine 
level > 1.5 
mg/dL 
 Give 125 mg 
vancomycin 4 times per 
day, or  
 200 mg fidaxomicin 
twice a day 
Strong/High 
 
Strong/High 
Initial 
recurrence 
  Use tapered and pulsed 
regimen with 
vancomycin if standard 
treatment plan was used. 
For example, start with 
125 mg 4 times a day for 
10-14 days, twice a day 
for a week, once a day 
for 7 days, then every 
two or three days for 2-8 
weeks, or  
 Give 200 mg 
fidaxomicin twice a day 
for 10 days if 
vancomycin was used to 
treat the first episode 
Weak/Low 
 
 
 
 
 
 
 
 
Weak/Moderate 
Second and 
subsequent 
recurrence 
  Use tapered and pulsed 
regimen with 
Weak/Low 
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vancomycin as 
explained for initial 
recurrence, or  
 125 mg vancomycin 4 
times a day for 10 days, 
then use 400 mg 
rifaximin three times a 
day for 20 days, or  
 200 fidaxomicin 2 times 
a day for 10 days, or  
 Fecal microbiota 
transplantation 
 
Weak/Low 
 
 
 
Weak/Low 
 
 
Strong/Moderate 
 
 Use of fecal microbiota transplantation for the treatment of CDI 
Although it was thought that developing narrow-spectrum antibiotics like 
fidaxomicin will both treat CDI and prevent its recurrence, the rate of CDI recurrence is 
still around 20-25% (Eyre et al., 2012). For the patients with recurrent CDI, who have 
failed to respond to antibiotics, fecal microbiota transplantation (FMT) has recently 
emerged as an alternative way to restore gut microbiota. The benefits of FMT include 
low cost, low risk, and high success rate, and thus FMT has been increasingly recognized 
as a promising option for refractory and recurrent CDI.  
 
There are a number of randomized clinical trials that compare FMT to placebo or 
vancomycin therapy (Table 3). In 2013, an open-labelled, randomized controlled study 
was published by van Nood et al., in which 43 elderly patients with recurrent CDI were 
enrolled (van Nood et al., 2013). Recurrent CDI was defined as a relapse of CDI after 
undergoing recommended antibiotic therapy described in the previous section. Exclusion 
criteria were recent chemotherapy, human immunodeficiency virus (HIV) infection, 
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prolonged use of immunosuppressants, antibiotics other than for treating CDI, or 
vasopressors, and admission to intensive care unit. Patients meeting the criteria were 
randomized into one of 3 groups: donor-feces infusion group (n=17), vancomycin group 
(n=13) and vancomycin with bowel lavage group (n=13). The donor-feces infusion group 
received 500 mg of oral vancomycin 4 times a day for 4-5 days and bowel lavage on the 
last day of antibiotic treatment before receiving the suspension of donor feces through a 
nasoduodenal tube. The vancomycin group followed a standard regimen, where 500 mg 
of oral vancomycin was given 4 times a day for 2 weeks. The last group had bowel 
lavage in addition to following standard vancomycin regimen. Donors were comprised of 
healthy volunteers free of any transmissible disease, such as HIV, hepatitis A, B, and C. 
Among the 16 patients who received FMT, 13 (81%) were cured after first infusion. The 
3 patients who did not resolve after first procedure underwent second infusion and 2 of 3 
patients were cured after second infusion, giving an overall success rate of 94% in the 
FMT treatment arm. In the vancomycin group, only 4 (31%) patients had resolved and in 
the vancomycin with bowel lavage group, 3 (23%) patients were cured (P<0.01 for 
success rate after first infusion and P<0.001 for overall cure rate). The rate of recurrence 
after initial therapy was 6% (1 of 16) for donor-feces infusion group, 62% (8 of 13) in the 
vancomycin group, and 54% (7 of 13) in the vancomycin with bowel lavage group 
(Figure 3).  
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Figure 3. Rate of resolution of CDI. Patients who received an infusion of donor-feces 
(overall) had significantly higher cure rates compared to patients who received either 
vancomycin alone or vancomycin with bowel lavage. From van Nood et al., 2013. 
 
Adverse events were similar among the three treatment arms, and in the FMT 
treated group, patients had increased fecal microbiota diversity, similar to that in the 
donors. patients These results indicate that FMT may be a potential treatment for multiple 
episodes of recurrent CDI. However, because FMT was performed in patients pre-treated 
with a short course of vancomycin and bowel lavage, it is unclear whether these had 
significant contributions to the efficacy of FMT. The question of whether FMT should be 
recommended for the first recurrence still remains unanswered.  
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To investigate whether FMT is effective as a treatment for an initial episode of 
CDI compared to vancomycin, Camacho-Ortiz et al. published results from a 
randomized, open, two-arm pilot study in 2017. In this study, 19 patients that were 
enrolled were over 18 years of age, had been diagnosed with CDI for the first time, and 
had no history of being treated for CDI (Camacho-Ortiz et al., 2017). CDI was 
considered resolved when patients met at least 2 of the following: 1) more than 2-point 
decrease on the Bristol scale, 2) at least 50% reduction in bowel movements within 72 
hours after receiving FMT, 3) no fever, and d) no abdominal pain. For this study, 19 
patients were randomized into two groups: one group of patients with CDI received 250 
mg of vancomycin (n=10) every 6 hours for 10 to 14 days, whereas the other group 
received FMT (n=9) via nasojejunal route, endoscopy or colonoscopy. In the vancomycin 
group, 8 of 9 (88.9%) patients were resolved, and in the FMT treatment group, 4 of 7 
(57.1%) patients were resolved after first procedure and 5 of 7 (71.4%) patients were 
resolved after second procedure (Figure 4). Furthermore, it was determined that after 
FMT, the microbial composition in the patient samples was different from that in the 
healthy donors’ pool.  
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Figure 4. Rate of resolution (%) of initial CDI in patients treated with FMT and 
vancomycin. Dark grey column in FMT group represents the resolution rate after a single 
procedure, and light grey column represent the resolution rate after the second procedure. 
From Camacho-Ortiz et al., 2017 
 
In their discussion, the authors stated that this finding may be due to the age 
difference between patients and donors, as microbiota diversity is known to change as 
people age (Yatsunenko et al., 2012). They also note that although the patients in the 
study were never treated for their first episode of CDI, they may have received antibiotics 
to treat diseases other than CDI. Another important limitation as a pilot study, the sample 
size was only 16 after eliminating patients who were lost to follow-up. This resulted in P 
values that were usually greater than 0.5. In order for the results to be significant, a full 
RCT with a much larger number of participants and fewer confounding factors is needed. 
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In 2018, Dubberke et al. reported results from a randomized, double-blinded, 
controlled clinical trial that compared 1 or 2 doses of microbiota-based drug (RBX2660) 
to a placebo in treating recurrent CDI. Each dose of the study product RBX2660 
contained 150 mL of suspension with at least 107 organisms/mL, and the placebo 
contained saline solution as a control (Dubberke et al., 2018). The study involved 133 
subjects, who had 2 or more recurrences of CDI. The subjects were randomized into: 
group A, receiving 2 doses of RBX2660 (n=45), group B, receiving 2 doses of placebo 
(n=44), and group C, receiving 1 dose of RBX2660 and 1 dose of placebo (n=44). The 
administration of two doses via enema in each group was about 7 days apart. Resolution 
of CDI was defined as the absence of diarrhea without the need for antibiotics until 8 
weeks after receiving first dose. The cure rate was 61% (25 of 41 patients) for group A, 
45% (20 of 44 patients) for group B, and 67% (28 of 42 patients) for group C (Figure 5).  
 
Figure 5. Efficacy of different doses of RBX2660 and placebo. Grp A = patients who 
received 2 doses of RBX2660, Group B = patients who received 2 doses of placebo, 
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Group C = patients who received 1 dose of RBX2660 followed by 1 dose of placebo, and 
Grp A+C = overall efficacy of patients who received RBX2660. From Dubberke et al., 
2018. 
 
Interestingly, the difference was only significant between group B (placebo) and 
group C (study product followed by placebo), not between group A (2 doses of study 
product) and group B (placebo). These results suggest that a single dose of the study 
product is sufficient in treating recurrent CDI compared to a placebo. However, it should 
be noted that the placebo group had surprisingly high response rate, which contrasts the 
previous studies, in which FMT had significantly higher success rate compared to 
standard vancomycin therapy. Furthermore, the authors note that using different tests for 
the diagnosis of CDI may have contributed to the results. For example, most of the 
patients (n=103) were diagnosed using nucleic acid amplification test (NAAT), which has 
been associated with overdiagnosis (Polage et al., 2015). This could mean that some of 
the patients may not have had active recurrent CDI during enrollment. In order to 
accurately determine the efficacy of FMT in treating CDI, future studies should consider 
including a placebo group as a control and determine a method to accurately confirm the 
presence of CDI.  
 
Compared to clinical trials that suggest FMT as an effective treatment for CDI, 
Hota et al. reported an open-label, randomized, controlled trial, in which FMT had a 
relatively low response rate (Hota et al., 2017). In this study, the efficacy of using 14 
days of oral vancomycin followed by single FMT was compared with 6 weeks of pulsed 
and tapered regimen of oral vancomycin (Hota et al., 2017). CDI was diagnosed when 
 17 
patients had more than 2 episodes of CDI confirmed using enzymatic immunoassay for 
C. difficile toxin. Exclusionary criteria included immunocompromised diseases, active 
and severe colitis, hypersensitivity or intolerance to vancomycin, chronic diseases 
associated with diarrhea, planned procedures that may cause diarrhea, or planned surgery 
that require use of antibiotics, pregnancy. In the vancomycin taper group, patients 
received 125 mg of oral vancomycin every 6 hours for 14 days and a taper of 125 mg of 
vancomycin over the next 4 weeks – every 12 hours during the first week, every 24 hours 
during the second week, every 48 hours during the third week, and every 72 hours during 
the fourth week. In the FMT group, patients received 125 mg of vancomycin orally every 
6 hours for 14 days, followed by a single FMT 48 hours after the last dose of 
vancomycin. Resolution of CDI was defined as the absence of CDI within 120 days of 
follow-up period. In this study, 30 patients were randomized to receive either: taper 
vancomycin (n=14) or FMT (n=16), and most of these patients had a history of multiple 
cases of CDI and failed to respond to vancomycin taper therapy prior to enrollment. 
Interestingly, 56.2% of patients in FMT group and 41.7% of patients in the vancomycin 
group experienced relapse during the follow-up period. This corresponds to 43.8% cure 
rate for FMT group and 58.3% for taper vancomycin group. In their discussion, the 
authors state that lower cure rates in the current study may indicate that previous studies 
may include overestimations due to lack or a control arm and the presence of many 
limitations including heterogeneous methodologies. It is also noted that higher success 
rates in other studies may be in part due to patients who were cured from treatment they 
received prior to enrollment. However, this study has its own limitations, including small 
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sample size, open-label study, the lack of bowel preparation in patients, the mass of 
donor stool, and short retention time. Therefore, this study further necessitates the 
development of a standardized, optimal protocol for FMT that includes methodologies for 
selecting donor, time, route of administration, and manufacturing microbiota suspension.  
 
Table 3. Trials comparing FMT with placebo or vancomycin therapy 
 van Nood et al. 
(2013) 
Camacho-Ortiz 
et al. (2017) 
Dubberke et al. 
(2018) 
Hota et al. 
(2017) 
Country (No. 
of sites) 
Netherlands (1) Mexico (1) USA/Canada 
(21) 
Canada (1) 
Inclusion 
criteria 
CDI recurrence 
after 
undergoing at 
least one 
antibiotic 
therapy (van 
>125 mg qid, 
for > 10 days; 
metronidazole 
500 mg tid for 
> 10 days); 
positive 
Meridian A/B 
toxin premier 
test 
First CDI at 
least 48 hours 
after admitted 
At least 2 
recurrences of 
CDI 
At least 2 
recurrences of 
CDI after 
receiving at 
least one oral 
van regimen; 
CDI confirmed 
by laboratory 
or pathology 
Exclusion 
criteria 
Compromised 
immune 
system, recent 
chemotherapy, 
HIV with CD4 
less than 240, 
use of 
prednisone, use 
of antibiotics 
for conditions 
other than CDI, 
use of 
vasopressors, 
Toxic 
megacolon, 
high risk of 
intestinal 
perforation, 
pregnancy, 
presence of 
neoplasms in 
colon 
Ongoing or 
planned 
antibiotic use, 
chronic 
diarrhea other 
than from CDI, 
compromised 
immune 
system, history 
of IBD, and 
pregnancy 
Neutropenia, 
graft-vs-host 
disease, 
admission to 
ICU for CDI, 
active severe 
colitis, 
hypersensitivity 
or intolerance 
to van, and 
chronic GI 
illness 
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pregnancy, 
admission to 
ICU 
Sample size 
(randomized 
and analyzed) 
Randomized 
(n=35); FMT 
(n=16); van 
(n=12); van 
and bowel 
lavage (n=13) 
Randomized 
(n=19); van 
(n=9); FMT 
(n=7) 
Randomized 
(n=127); 2 
doses of 
RBX2660 
(n=41); 2 doses 
of placebo 
(n=44); 1 dose 
of RBX2660 
and 1 dose of 
placebo (n=42) 
 
Follow-up 
period 
10 weeks 3 days 8 weeks 120 days 
Exclusion 
criteria for 
donors 
Risk of any 
infectious 
disease, 
presence of GI 
illness/ 
complaint, 
family history 
of GI cancer or 
IBD, general 
malaise, use of 
medications 
that may affect 
FMT 
preparation 
Use of proton-
pump 
inhibitors, 
immune-
suppressants, 
antibiotics, 
hospitalization, 
diarrhea within 
3 months 
before 
collection, 
high-risk 
sexual 
behavior, 1st-
degree relative 
with diabetes, 
GI disease or 
cancer, history 
of abdominal 
surgery  
Not provided 
(use of 
standardized 
drug as an 
intervention) 
Risk of any 
infectious 
disease 
Pre-treatment 500 mg of van 
qid for 4 days 
and bowel 
lavage 
No prior 
treatment for 
CDI 
Antibiotics up 
to 24-48 hours 
before 
receiving 
reatment 
125 mg of van 
qid for 2 weeks  
Intervention FMT following 
pre-treatment 
phase 
FMT 1 or 2 doses of 
RBX2660, 
given 1 week 
apart 
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Mode of 
delivery 
Naso-duodenal 
infusion 
Naso-jejunal 
infusion, 
superior 
endoscopy, or 
colonoscopy 
Enema Enema 
Non-FMT or 
control group 
500 mg of van 
qid for 14 days 
or van with 
bowel lavage 
on Day 4 or 
Day 5 
250 mg van qid 
for 10-14 days 
2 doses of 
placebo, given 
1 week apart 
Tapered van 
therapy for 6 
weeks: 125 mg 
of van qid for 2 
weeks followed 
by 4 weeks of 
tapered van 
Primary end 
point 
Absence of 
CDI-associated 
diarrhea within 
10 weeks 
Must satisfy at 
least 2 of the 
following: 1) 
>2 pt reduction 
on Bristol 
scale, 2) >50% 
reduction in 
frequency of 
bowel 
movements 
within 72 hours 
post FMT, 3) 
absence of 
fever, and 4) 
absence of 
abdominal pain 
Absence of 
diarrhea and no 
recurrence of 
CDI between 
receiving the 
first dose and 8 
weeks after 
receiving the 
second dose 
Absence of 
CDI within 120 
days 
qid = 4 times per day; tid = 3 times per day; van = vancomycin; IBD = inflammatory 
bowel disease; ICU = intensive care unit; GI = gastrointestinal; pt = point 
From (Moayyedi, Yuan, Baharith, & Ford, 2017) 
 
In addition to studying the efficacy of FMT in patients with recurrent CDI (Table 
3), there are many clinical trials that compare different FMT modalities. It should be 
noted that because these studies lack control groups, they may not be useful in 
determining the efficacy of FMT in elderly patients with CDI. However, the results from 
these studies are important in determining the optimal FMT methodologies. 
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In 2016, Lee et al. reported results from a randomized, double-blinded clinical 
trial that compares frozen FMT to fresh FMT. Using frozen samples would lower the 
cost, decrease frequency of donor screenings, make FMT more readily available, and 
allow centers without laboratory facilities to perform FMT (Lee et al., 2016). Patients 
were enrolled if they were diagnosed with CDI confirmed by enzyme immunoassay or 
polymerase chain reaction that was positive for C. difficile toxin B gene and had more 
than 3 unformed stools within 24 hours for at least 2 days. The study was comprised of 
178 CDI patients, who were randomized to receive either fresh (n=91) and frozen (n=87) 
FMT. Any use of suppressive antibiotics was discontinued 1-2 days prior to receiving 
FMT. Fecal samples collected from healthy volunteers were processed, stored fresh or 
frozen, and used for FMT within 24 hours of collection. CDI resolution was defined as 
not using antibiotics and the absence of CDI-associated diarrhea within 13 weeks after 
receiving 1 or 2 FMTs. Results indicate that the overall efficacy between the two groups 
was comparable, with 83.5% (76 of 91 patients) resolution in the frozen FMT group and 
85.1% (74 of 87 patients) resolution in the fresh FMT group. These findings suggest that 
frozen microbiota suspensions can be used to achieve similar efficacy as fresh samples, 
while reducing the cost and making FMT more applicable in different care facilities. In 
addition to the finding that frozen FMT may be a reliable preparation technique, it is 
noteworthy that the rate of resolution using FMT was high even though the study 
involved many patients with significant morbidity. More than 50% of the patients were 
hospitalized at the time of treatment and had moderate to severe cases of CDI. However, 
some limitations of the study include a short follow-up period of 13 weeks, a relatively 
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low resolution rate after single FMT (62%), a low number of donors and a lack of control 
group. As such, the results from this study should be considered when optimizing FMT 
protocols, rather than determining the viability and durability of FMT.  
 
In order to determine whether the route of delivery of FMT affects its efficacy, 
Kao et al. published results from a non-inferiority, unblinded, randomized clinical trial, in 
which FMT by oral capsule was compared with colonoscopy (Kao et al., 2017). Enrolled 
patients had a mean age of 58 years and had more than 3 episodes of CDI, defined as 
having more than 3 unformed stools every 24 hours (Kao et al., 2017). Exclusion criteria 
included undergoing treatment for cancer, requiring the use of antibiotics for diseases 
other than CDI, having chronic diarrhea, or having a severe or complicated CDI. In this 
study, 116 patients were randomized to receive FMT by either oral capsule (n=57) or 
colonoscopy (n=59). In both groups, patients received 125 mg of oral vancomycin 4 
times per day up to 24 hours prior to receiving frozen FMT. Resolution of CDI, defined 
as the absence of recurrent CDI within 12 weeks after FMT, was achieved in 96% of 
patients in both groups. In the discussion, the authors state that this higher rate of 
resolution compared to previous studies may be due to a higher dose of FMT used in this 
study, suggesting FMT response could be dose dependent. In addition, bowel lavage was 
not performed as a part of procedure, so the effect of residual vancomycin cannot be 
ruled out. Some major limitations of the study include the absence of a placebo group and 
the exclusion of patients with severe and complicated cases of CDI. These factors limit 
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the generalizability of the findings, nonetheless it can be inferred that administration of 
oral capsules is non-inferior to colonoscopy. 
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DISCUSSION 
 
In the last decade, FMT emerged as a viable, safe and well-accepted option for 
patients with CDI. Despite its compelling nature, there is still a limited number of 
randomized, controlled trials that compare various forms and routes of administration of 
FMT to those of standard antibiotic regimen or placebo (Table 3). However, only limited 
numbers of studies investigate the safety and efficacy in the elderly population, who are 
more likely to have multiple comorbidities than young adults. This review discusses 
literature that involved older patient population, yet the findings remain inconclusive.  
 
The efficacy of FMT in published studies ranges from 44% to 96% (Hota & 
Poutanen, 2018), which is mainly due to a lack of standardization of many variables.  
Although studies follow previously published literature in making a general protocol for 
FMT, they use different practices to confirm CDI in patients. It is important to use a 
specific method to diagnose CDI, as false positive results can lead to overestimation of 
the efficacy of FMT. In addition, as outlined in Table 3, inclusion and exclusion criteria 
for enrolling patients and stool donors varied widely among different trials. In terms of 
preparing for FMT, studies differed in the volume of FMT (amount of microbiota in 
samples), the mass of donor stool, and the pre-treatment. Some studies involved no 
treatment with antibiotics, whereas others used antibiotics along with bowel lavage. 
These differences would further result in overestimation of the efficacy due to 
vancomycin as a confounding factor. All of these limitations in the study design make it 
difficult determine whether FMT is actually effective compared to standard vancomycin 
 25 
therapy. Furthermore, many studies comparing different FMT modalities lacked a 
placebo group, making it impossible to determine the efficacy of FMT administered by 
each delivery method. Nonetheless, general consensus is that the adverse events and 
serious adverse events of FMT are comparable to other forms of treatment. With further 
research, FMT could be a safe, cost-effective, and powerful therapy to treat patients with 
not just CDI, but a general dysbiosis of intestinal microbiota. 
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